Patents
Literature
4 results about "Refractory Disease" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A refractory disease is a disease that resists treatment, especially an individual case that resists treatment more than is normal for the specific disease in question. Subclinical disease Also called silent disease , silent stage , or asymptomatic disease .
Antibody-drug conjugates containing two or more functional small molecule compounds for enhancing treatment of refractory diseases
PendingCN121729249APolypeptide with localisation/targeting motifOrganic active ingredientsAntiendomysial antibodiesPharmaceutical drug
The invention provides an antibody drug conjugate containing a functional small molecule side chain. The antibody drug conjugate is used for enhancing the targeted therapeutic effect of cancers and refractory diseases. The invention also relates to a preparation method of the conjugate, a pharmaceutical composition and a method for treating refractory diseases.
Owner:HANGZHOU SEEHE BIOTECHNOLOGY CO LTD +2
Anti-CD276 monoclonal antibody, its conjugates, and use thereof
PCT designated stageWO2026108289A1Polypeptide with localisation/targeting motifPharmaceutical delivery mechanismAntiendomysial antibodiesHumanized antibody
The humanized monoclonal antibodies and the antibody drug conjugates targeting CD276 (B7-H3), derived from the murine monoclonal antibody clone 8H9. These antibodies and the antibody drug conjugates exhibit high affinity and specificity for human CD276, a member of the B7 family of immune regulatory proteins, which is overexpressed in various tumors and involved in immune checkpoint modulation. The humanized antibodies and the antibody drug conjugates are applied for targeted treatment of cancers and refractory diseases.
Owner:HANGZHOU SEEHE BIOTECHNOLOGY CO LTD +1
A class of protac molecules with crizotinib as a target head, preparation method and application
The application discloses a kind of PROTAC molecules with crizotinib as target head, preparation method and application, belong to the field of biological medicine;Preparation method includes: chloro carboxylic acid, thionyl chloride and anhydrous DMF are mixed, after heating reflux reaction, remove thionyl chloride, obtain acyl chloride;Pomalidomide, acyl chloride, organic solvent are mixed and reacted, then filtered to obtain intermediate M;Intermediate M, crizotinib, Na2CO3 are mixed and reacted, then filtered to obtain the PROTAC molecule with crizotinib as target head.The in vitro biological evaluation shows that the new PROTAC molecule can efficiently and selectively induce ubiquitination and degradation of target protein, and exhibits significant antiproliferative activity in drug-resistant tumor cell models and animal models;The application proves that the PROTAC molecule has great potential in overcoming drug resistance of traditional inhibitors, and provides a promising lead compound for developing new therapies for treating refractory diseases such as cancer.
Owner:BENGBU MEDICAL COLLEGE
PIM1 inhibitors for the treatment of myeloproliferative neoplasms
A method for treating myeloproliferative neoplasms is provided, particularly for treating human patients with poor bone marrow function and relapsed or refractory diseases that are difficult to treat. The disclosed method has the following structure: [Case 1] The method comprises administering a compound (1) having JPEG2026509318000030.jpg3762 or a pharmaceutically acceptable salt thereof, and optionally a JAK kinase inhibitor and / or an ACVR inhibitor, to a human subject in need.
Owner:SUMITOMO PHARMA AMERICA INC